Oncopeptides virtuella kapitalmarknadsdag
30 november, 2020
“Building a Fully Integrated Biotechnology Company”. Hela Kapitalmarknadsdagen hölls på engelska.
The Program
- Introduction and Strategy for Value Growth – Marty J Duvall, CEO Oncopeptides
- Multiple Myeloma
“Myeloma remains one of the largest unmet medical needs within hematology”
o Assistant Professor Joshua Richter, MD. Icahn School of Medicine at Mount Sinai Hospital, New York - Relapsed refractory multiple myeloma and melflufen – clinical experience with melflufen – Panel discussion
o Professor Paul Richardson, MD, Dana-Farber Cancer Institute, Boston
o Associate Professor Maria-Victoria Mateos, MD, PhD, University Hospital, Salamanca
Moderated by Klaas Bakker, MD, PhD, CMO Oncopeptides - The clinical development program for melflufen
“Understanding how melflufen can help patients the most” – Jakob Lindberg, CSO Oncopeptides - Successfully making the drug available for patients in the US
Overview of US launch of melflufen – Marty J Duvall, CEO Oncopeptides - Questions and Answers
Den virtuella kapitalmarknadsdagen webbsändes live och spelades in
To get to the webcast klick on the link below:
https://tv.streamfabriken.com/oncopeptides-cmd-2020